Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Cancer statistics, 2016Registry Study · 2016 · 16,204 citations
2. 2Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acidsReview · 2016 · 68 citations
3. 3Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNAOriginal Research · 2002 · 138 citations
4. 4Circulating tumor DNA as a non‐invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor typesEarly-Phase Clinical Trial · 2014 · 273 citations
5. 5Circulating tumor cells (CTC) and KRAS mutant circulating free DNA (cfDNA) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancerPilot Study · 2015 · 181 citations